IFF eyeing acquisitions again as it sells off pharma unit—but no more ‘Frutaroms’

On a call with Wall Street analysts after the Fortune 500 company reported its 2024 results, CEO Erik Fyrwald made it clear that acquisitions were back on the table—but with a more disciplined approach. Read More